By Turna Ray

NEW YORK (GenomeWeb News) – How broad can the claims in a gene patent be without impeding research and still be of financial value to the patent holder? While a US District Court judge in a pending high-profile anti-gene patenting case is currently mulling over the answer to this very question, researchers from Duke University used bioinformatics to estimate the reach of a claim from one of Myriad Genetics' patents on the BRCA1 gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.